His main research concerns Internal medicine, Cancer, Oncology, Chemotherapy and Cancer research. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery. His biological study spans a wide range of topics, including Monoclonal, Microsatellite instability and Pathology.
His Oncology research includes themes of Clinical endpoint, Clinical trial and Carcinoma. The Chemotherapy study combines topics in areas such as Prospective cohort study, Capecitabine and Oxaliplatin. His Cancer research research integrates issues from Mutation, Anaplastic lymphoma kinase, ALK inhibitor, Receptor tyrosine kinase and ROS1.
Jeeyun Lee focuses on Internal medicine, Oncology, Cancer, Cancer research and Chemotherapy. His Internal medicine research incorporates themes from Gastroenterology, Surgery and Pathology. In his study, Cisplatin is inextricably linked to Capecitabine, which falls within the broad field of Oncology.
His research integrates issues of Immunohistochemistry, Radiation therapy, Microsatellite instability and Hazard ratio in his study of Cancer. His work deals with themes such as Cell growth, Mutation, KRAS, Gene and Antibody, which intersect with Cancer research. His Chemotherapy study frequently links to adjacent areas such as Clinical endpoint.
The scientist’s investigation covers issues in Internal medicine, Cancer, Cancer research, Oncology and Chemotherapy. In his research, Capecitabine is intimately related to Gastroenterology, which falls under the overarching field of Internal medicine. Jeeyun Lee studied Cancer and Hazard ratio that intersect with Adjuvant therapy.
His work carried out in the field of Cancer research brings together such families of science as Cell growth, RNA, Immune system, KRAS and Antibody. His Oncology research is multidisciplinary, relying on both Biomarker, Primary tumor, Advanced gastric cancer and Immunotherapy. His study on Chemotherapy is mostly dedicated to connecting different topics, such as Randomized controlled trial.
His primary areas of investigation include Internal medicine, Cancer, Oncology, Cancer research and Chemotherapy. His Internal medicine study typically links adjacent topics like Gastroenterology. His Cancer research incorporates elements of Stage, Receptor, Microsatellite instability and Cohort.
His Oncology research is multidisciplinary, relying on both Cohort study, Young adult, Survival rate, Biomarker and Immunotherapy. His Cancer research research incorporates elements of KRAS, Antibody, Kinase and Phase i study. The various areas that he examines in his Chemotherapy study include Stage ii, Visual acuity and Vandetanib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu.
The Lancet (2017)
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Yung Jue Bang;Young Woo Kim;Han Kwang Yang;Hyun Cheol Chung.
The Lancet (2012)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu;Jeeyun Lee;Michael Nebozhyn;Kyoung-Mee Kim.
Nature Medicine (2015)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim;Razvan Cristescu;Adam J. Bass;Kyoung Mee Kim.
Nature Medicine (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo.
The Lancet (2018)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang;Soon Il Lee;Do Hyoung Lim;Keon Woo Park.
Journal of Clinical Oncology (2012)
Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study
Jeeyun Lee;Cheolwon Suh;Yeon Hee Park;Young H. Ko.
Journal of Clinical Oncology (2006)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel.
Cancer Discovery (2017)
Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA
Richard B. Lanman;Stefanie A. Mortimer;Oliver A. Zill;Dragan Sebisanovic.
PLOS ONE (2015)
Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial
Jeeyun Lee;Do Hoon Lim;Sung Kim;Se Hoon Park.
Journal of Clinical Oncology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: